Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "IMI"

2718 News Found

Biocon Biologics gets complete response letter from USFDA for Biosimilar Insulin Aspart
Drug Approval | October 09, 2023

Biocon Biologics gets complete response letter from USFDA for Biosimilar Insulin Aspart

The company had submitted a comprehensive Corrective and Preventive Action (CAPA) plan in September 2022


Biocon Biologics receives European Commission approval for biosimilar of Aflibercept ‘Yesafili’
Drug Approval | September 21, 2023

Biocon Biologics receives European Commission approval for biosimilar of Aflibercept ‘Yesafili’

The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway


Biocon Biologics completes integration of Viatris Biosimilars’ business in North America
News | September 07, 2023

Biocon Biologics completes integration of Viatris Biosimilars’ business in North America

Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris


Sandoz plans to build a Biosimilar Technical Development Center in Slovenia
Biotech | July 20, 2023

Sandoz plans to build a Biosimilar Technical Development Center in Slovenia

Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026


Biocon Biologics' Hulio Biosimilar to Humira now available in the US
News | July 04, 2023

Biocon Biologics' Hulio Biosimilar to Humira now available in the US

The launch of HULIO in the United States is an important milestone for Biocon Biologics


Aurobindo's subsidiary to withdraw application for EU marketing authorization of two biosimilars
News | June 26, 2023

Aurobindo's subsidiary to withdraw application for EU marketing authorization of two biosimilars

This request for withdrawal of the two dossiers was made after necessary consultations and receiving guidance from EMA


LVPEI raises awareness on antimicrobial resistance among medical students
News | June 23, 2023

LVPEI raises awareness on antimicrobial resistance among medical students

Antimicrobial Resistance (AMR) poses a significant threat to global healthcare systems and patient safety


Sandoz introduces Act4Biosimilars Action Plan to accelerate patient access to biosimilar medicines
News | June 19, 2023

Sandoz introduces Act4Biosimilars Action Plan to accelerate patient access to biosimilar medicines

Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic


Samsung Biologics and Pfizer collaborate for long-term manufacturing of biosimilars portfolio
News | June 14, 2023

Samsung Biologics and Pfizer collaborate for long-term manufacturing of biosimilars portfolio

Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio


Dr. Reddy's completes Phase I study (IV route) of a proposed biosimilar of tocilizumabp
News | June 06, 2023

Dr. Reddy's completes Phase I study (IV route) of a proposed biosimilar of tocilizumabp

The successful outcome of this study represents an important milestone in Dr. Reddy's commitment to make highquality biosimilar products more accessible and affordable